Ascendis Pharma A (ASND) Non Operating Income (2013 - 2025)

Ascendis Pharma A (ASND) has 13 years of Non Operating Income data on file, last reported at $213.7 million in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Income rose 142.83% year-over-year to $213.7 million; the trailing twelve-month figure through Dec 2025 stood at $370.6 million (up 104.27% YoY), and the FY2025 full-year result was $213.7 million, up 139.74% from the prior year.
• Non Operating Income advanced to $213.7 million in Q4 2025, from $88.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $213.7 million in Q4 2025 to a low of $24.5 million in Q4 2021.
• A 5-year average of $79.0 million and a median of $40.1 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income gained 17.47% in 2022 and surged 142.83% in 2025, its largest moves.
• Tracing ASND's Non Operating Income over 5 years: stood at $24.5 million in 2021, then increased by 17.47% to $28.8 million in 2022, then soared by 39.49% to $40.1 million in 2023, then surged by 119.19% to $88.0 million in 2024, then jumped by 142.83% to $213.7 million in 2025.
• Business Quant data shows ASND's Non Operating Income at $213.7 million in Q4 2025, $88.0 million in Q4 2024, and $40.1 million in Q4 2023.